There are only a few alternative long-term therapies available for end-stage heart failure patients, including implantable mechanical devices and heart transplantation. Both alternatives have limitations. Hearts for transplanting are significantly limited by the availability of donors, require expensive and complex heart surgery, and subsequent burdensome and expensive life-long immunosuppressive medication.
Currently available implantable mechanical heart pumps called LVADs are expensive and lead to a high risk of thrombosis due to their rapidly moving thrombogenic parts in the bloodstream, as well as bleeding due to anticoagulation medication. Furthermore, they require complex open-heart surgery which also has a drastic impact on recovery time. Additionally, infections frequently occur due to the opening through the skin for cable connection, and patients experience a lower quality of life due to the external power source of the implanted device.
To address these current challenges, Syntach is developing a medical device for the treatment of patients with chronic left ventricular heart failure. Our patented innovation is an entirely new approach to heart failure treatment and works by restoring the natural function of the mitral valve plane that is reduced in heart failure patients. By providing a novel and effective product that eliminates the limitations of current treatment alternatives such as invasiveness, high costs, significant infection risk, thrombosis risk, external batteries and significant energy consumption, Syntach will have a unique place on the market. With our Syntach Cardiac Support device – the Syntach CS – we aim to increase patient survival rates, improve the patients’ quality of life and reduce healthcare costs, meeting both clinical and socio-economic needs.